This study tests a new drug, LY3457263, for people with Type 2 Diabetes who aren't reaching their blood sugar goals with semaglutide or tirzepatide. The key measure is the change in hemoglobin A1c (HbA1c), which shows average blood sugar over a few months.
Eligibility: To join, you need Type 2 Diabetes, a body mass index (BMI) over 27, and stable weight and medication for the past three months. You cannot participate if you have Type 1 Diabetes, recent heart problems, or have used insulin in the past year.
Key Points:
- **Duration**: The study lasts about 9 months.
- **Treatment**: You must be on stable doses of semaglutide or tirzepatide.
- **Exclusions**: Recent heart issues or weight loss medications disqualify participation.